Introduction: Diabetic foot ulcer (DFU) is a high prevalence complication of diabetes mellitus that significantly impairs the health related quality of life (HRQoL) of patients and is characterised by a prolonged length of hospital stay (LOS). DFU represents a complex clinical scenario. The prevalence of diabetic foot in the global population is 6.3%. The MiFrAADiF trial demonstrated positive results in terms of the healing of DFUs after the injection of micro-fragmented autologous adipose tissue at the minor amputation stump. The impact of this technique on HRQoL and LOS versus standard care has not yet been determined.
Health Related Quality of Life Outcomes and Length of Hospital Stay After Micro-Fragmented Autologous Adipose Tissue Injection in Minor Amputations for Diabetic Foot Ulceration (MiFrAADiF trial): Results From a Randomised Controlled Single Centre Clinical Trial / Leone, N; Gennai, S; Covic, T; Migliari, M; Rossi, F; Pizzarelli, G; Ferri, A; Silingardi, R. - In: EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY. - ISSN 1078-5884. - 63:2(2022). (Intervento presentato al convegno 35th ESVS Annual Meeting tenutosi a Rotterdam, The Netherlands nel 28 – 29 September ,2021) [https://doi.org/10.1016/j.ejvs.2021.12.002].